Acquired by Jazz Pharmaceuticals (JAZZ)
GWPH - GW Pharmaceuticals plc
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Type: Equity
GWPH price evolution
GWPH
| (in millions $) | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 | 31 Mar 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $486.75 | $480.33 | $477.56 | $500.94 |
| Short term investments | ||||
| Net receivables | $71.17 | $80.42 | $80.36 | $62.21 |
| Inventory | $129.14 | $115.04 | $99.62 | $89.06 |
| Total current assets | $729.53 | $720.27 | $687.72 | $672.75 |
| Long term investments | ||||
| Property, plant & equipment | $168.88 | $153.5 | $147.44 | $146.08 |
| Goodwill & intangible assets | $12.52 | $12.52 | $12.59 | $12.91 |
| Total noncurrent assets | $209.98 | $189.99 | $182.86 | $181.63 |
| Total investments | ||||
| Total assets | $939.51 | $910.26 | $870.58 | $854.38 |
| Current liabilities | ||||
| Accounts payable | $21.87 | $17.84 | $16.24 | $18.34 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $159.81 | $140.29 | $118.5 | $103.47 |
| Long term debt | $27.58 | $24.83 | $24.73 | $25.18 |
| Total noncurrent liabilities | $38.62 | $35.52 | $35.14 | $35.9 |
| Total debt | $27.58 | $24.83 | $24.73 | $25.18 |
| Total liabilities | $198.42 | $175.81 | $153.64 | $139.37 |
| Shareholders' equity | ||||
| Retained earnings | -$896.09 | -$866.94 | -$854.75 | -$845.92 |
| Other shareholder equity | -$53.55 | -$71.42 | -$84.39 | -$83.05 |
| Total shareholder equity | $741.09 | $734.45 | $716.94 | $715 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $486.75 | $536.93 | $354.91 | $308.7 |
| Short term investments | ||||
| Net receivables | $71.17 | $48.88 | $2.12 | $14.36 |
| Inventory | $129.14 | $85.53 | $19.06 | $5.43 |
| Total current assets | $729.53 | $699.64 | $390.71 | $354.19 |
| Long term investments | ||||
| Property, plant & equipment | $168.88 | $152.68 | $82.38 | $55.89 |
| Goodwill & intangible assets | $12.52 | $6.96 | $6.96 | $8.01 |
| Total noncurrent assets | $209.98 | $182.61 | $99.82 | $71.94 |
| Total investments | ||||
| Total assets | $939.51 | $882.25 | $490.54 | $426.13 |
| Current liabilities | ||||
| Accounts payable | $21.87 | $9.99 | $9.74 | $54.24 |
| Deferred revenue | $8.41 | |||
| Short long term debt | $0.26 | |||
| Total current liabilities | $159.81 | $117.56 | $58.67 | $46.68 |
| Long term debt | $27.58 | $27.22 | $5.91 | $6.09 |
| Total noncurrent liabilities | $38.62 | $38.65 | $16.71 | $23.39 |
| Total debt | $27.58 | $27.22 | $5.91 | $6.35 |
| Total liabilities | $198.42 | $156.22 | $75.38 | $70.07 |
| Shareholders' equity | ||||
| Retained earnings | -$896.09 | -$837.96 | -$757.03 | -$380.83 |
| Other shareholder equity | -$53.55 | -$68.62 | -$75.19 | -$74.52 |
| Total shareholder equity | $741.09 | $726.03 | $415.16 | $356.06 |
| (in millions $) | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 | 31 Mar 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $148.22 | $137.05 | $121.3 | $120.63 |
| Cost of revenue | $10.42 | $7.63 | $8.71 | $10.77 |
| Gross Profit | $137.8 | $129.42 | $112.59 | $109.86 |
| Operating activities | ||||
| Research & development | $56.85 | $56.93 | $45.73 | $45.87 |
| Selling, general & administrative | $103.76 | $85.2 | $75.89 | $71.18 |
| Total operating expenses | $160.62 | $142.14 | $121.63 | $117.06 |
| Operating income | -$22.81 | -$12.72 | -$9.04 | -$7.19 |
| Income from continuing operations | ||||
| EBIT | -$26.27 | -$14.31 | -$7.4 | -$5.94 |
| Income tax expense | $2.61 | -$2.39 | $1.13 | $1.74 |
| Interest expense | $0.27 | $0.27 | $0.3 | $0.28 |
| Net income | ||||
| Net income | -$29.15 | -$12.19 | -$8.83 | -$7.96 |
| Income (for common shares) | -$29.15 | -$12.19 | -$8.83 | -$7.96 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $527.21 | $311.33 | $12.74 | $10.54 |
| Cost of revenue | $37.53 | $27.2 | $5.99 | $4.53 |
| Gross Profit | $489.67 | $284.13 | $6.75 | $6.01 |
| Operating activities | ||||
| Research & development | $205.4 | $142.68 | $153.74 | $142.37 |
| Selling, general & administrative | $336.04 | $259.88 | $141.82 | $53.37 |
| Total operating expenses | $541.44 | $402.56 | $295.55 | $195.75 |
| Operating income | -$51.77 | -$118.42 | -$288.8 | -$189.74 |
| Income from continuing operations | ||||
| EBIT | -$53.92 | -$8.12 | -$290.12 | -$194.12 |
| Income tax expense | $3.08 | -$0.18 | $3.8 | -$26.52 |
| Interest expense | $1.12 | $1.09 | $1.25 | $0.95 |
| Net income | ||||
| Net income | -$58.13 | -$9.02 | -$295.17 | -$168.56 |
| Income (for common shares) | -$58.13 | -$9.02 | -$295.17 | -$168.56 |
| (in millions $) | 31 Dec 2020 | 30 Sep 2020 | 30 Jun 2020 | 31 Mar 2020 |
|---|---|---|---|---|
| Net income | -$29.15 | -$12.19 | -$8.83 | -$7.96 |
| Operating activities | ||||
| Depreciation | $3.61 | $3.63 | $2.86 | $2.66 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $17.91 | $15.77 | $13.32 | $11.36 |
| Total cash flows from operations | $5.93 | $1.03 | -$15.74 | -$18.6 |
| Investing activities | ||||
| Capital expenditures | $1.43 | -$3.81 | -$5.92 | -$13.3 |
| Investments | ||||
| Total cash flows from investing | -$4.98 | -$3.81 | -$5.92 | -$13.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | $0.97 | -$1.22 | $0 |
| Net borrowings | -$0.23 | -$0.22 | -$0.21 | -$0.22 |
| Total cash flows from financing | -$0.23 | $0.75 | -$1.43 | -$0.21 |
| Effect of exchange rate | $5.7 | $4.81 | -$0.28 | -$3.89 |
| Change in cash and equivalents | $6.42 | $2.77 | -$23.38 | -$36 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$58.13 | -$9.02 | -$295.17 | -$168.56 |
| Operating activities | ||||
| Depreciation | $12.76 | $9.24 | $9.29 | $6.75 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $58.36 | $48.03 | $31.63 | $15.18 |
| Total cash flows from operations | -$27.39 | -$123.47 | -$231.87 | -$141.11 |
| Investing activities | ||||
| Capital expenditures | -$21.6 | $61.63 | -$32.89 | -$20.56 |
| Investments | ||||
| Total cash flows from investing | -$28.01 | $61.63 | -$32.89 | -$19.54 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.25 | $2.88 | $298.55 | $0.12 |
| Net borrowings | -$0.88 | -$0.93 | -$0.8 | -$0.27 |
| Total cash flows from financing | -$1.13 | $1.95 | $297.75 | -$2.63 |
| Effect of exchange rate | $6.34 | $5.33 | -$0.24 | -$7.24 |
| Change in cash and equivalents | -$50.18 | -$54.56 | $32.76 | -$170.52 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 31.35M |
| Revenue | $527.21M |
|---|---|
| EBITDA | -$41.17M |
| EBIT | -$53.92M |
| Net Income | -$58.13M |
| Revenue Q/Q | 35.89% |
| Revenue Y/Y | 69.34% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 25.35 |
| Cash/Share | 15.53 |
| EPS | -$1.85 |
|---|---|
| ROA | -6.50% |
| ROE | -8.00% |
| Debt/Equity | 0.27 |
|---|---|
| Net debt/EBITDA | 7.00 |
| Current ratio | 4.57 |
| Quick ratio | 3.76 |